title: Effects of indapamide on atherosclerosis development in cholesterol-fed rabbits.
abstract: We examined the effect of indapamide (IND) on the development of atherosclerosis lesions in rabbits maintained on a 1% (wt/wt) cholesterol-enriched diet for a 16-week period. IND was supplemented to the diet at three different levels to correspond to doses of 0.1, 0.3, and 1 mg/kg/day. Throughout the treatment, dietary consumption and body weight gains were comparable among the experimental and control groups. IND had no significant effect on plasma cholesterol, triglycerides, or phospholipids concentrations. Despite the lack of effect of the drug on these parameters, its administration produced a tendency toward a reduction in the aortic content of cholesterol and a dose-dependent and significant decrease in aortic damage. In the aortic arch, the extent of intimal aortic surface covered by grossly discernible atherosclerotic lesions was decreased by IND 1 mg/kg/day from 11.02 +/- 1.10 to 6.00 +/- 1.00% (p < 0.05) and from 9.72 +/- 1.39 to 5.37 +/- 1.20% (p < 0.05) in the remaining thoracic sections. In addition, the former dose also reduced the number of lesions per square centimeter from 3.69 +/- 0.68 to 1.72 +/- 0.53% (p < 0.05), and from 3.37 +/- 0.85 to 1.55 +/- 0.46% (p < 0.05) in aortic arch and in thoracic sections, respectively. The possibility that IND reduces the development of atherosclerotic lesions produced by diet-induced hypercholesterolemia through a mechanism involving its calcium antagonist and/or its antioxidant activity is discussed.
authors.affiliation: Department of Pharmacology, School of Medicine, Universidad Complutense, Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Del Rio
authors.forename: T
authors.initials: T
authors.lastname: Chulia
authors.forename: A
authors.initials: A
authors.lastname: Merchan-Perez
authors.forename: M
authors.initials: M
authors.lastname: Remezal
authors.forename: S
authors.initials: S
authors.lastname: Valor
authors.forename: J
authors.initials: J
authors.lastname: Gonzalez
authors.forename: J A
authors.initials: JA
authors.lastname: Gutierrez
authors.forename: J A
authors.initials: JA
authors.lastname: Contreras
authors.forename: M A
authors.initials: MA
authors.lastname: Lasuncion
authors.forename: T
authors.initials: T
authors.lastname: Tejerina
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000959:Antihypertensive Agents / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D001011:Aorta / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D001161:Arteriosclerosis / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D002851:Chromatography, High Pressure Liquid; D004195:Disease Models, Animal; D004232:Diuretics / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006937:Hypercholesterolemia / Q000188:drug therapy; D007091:Image Processing, Computer-Assisted; D007190:Indapamide / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D010743:Phospholipids / Q000097:blood; D011817:Rabbits; D014280:Triglycerides / Q000097:blood
chemical_list: D000959:Antihypertensive Agents; D002791:Cholesterol, Dietary; D004232:Diuretics; D010743:Phospholipids; D014280:Triglycerides; D002784:Cholesterol; D007190:Indapamide